We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis (NVS) Reports Favorable Data on Enbrel Biosimilar
Read MoreHide Full Article
Novartis AG’s (NVS - Free Report) generic arm, Sandoz announced the publication of results from EGALITY study in the British Journal of Dermatology. The study showed that its biosimilar version of Amgen Inc.’s (AMGN - Free Report) blockbuster drug, Enbrel, Erelzi, is equivalent to the originator product in more than 500 adult patients over 52 weeks.
Erelzi was approved by the FDA in August this year for the treatment of various inflammatory conditions including rheumatoid arthritis, plaque psoriasis and psoriatic arthritis. The biosimilar candidate is under review in the EU where the submission was accepted last year. Notably, Erelzi is still to be launched in the U.S.
EGALITY included both the switched and continuous treatment arms. Patients were treated with Erelzi and Enbrel alternatively and it was seen that no clinically meaningful difference in safety and efficacy were observed between Erelzi and the originator product over the duration of the study. In addition the three treatment switches had no impact on the safety and efficacy of the biosimilar candidate.
Sandoz currently markets Zarxio in the U.S. a biosimilar version of Amgen Inc.’s (AMGN - Free Report) Neupogen. In addition, it has a strong pipeline of biosimilars including that of Roche Holding AG’s (RHHBY - Free Report) Rituxan. The company plans to launch five biosimilars for major oncology and immunology biologics across key geographies by 2020. Sandoz is well positioned in the biosimilars space based on its experience and capabilities in development, manufacturing and commercialization.
Novartis currently carries a Zacks Rank #3 (Hold).
Arbutus’s loss estimates narrowed from $2.15 to $1.74 for 2016 and from $1.96 to $1.51 for 2017 over the last 60 days. The company posted a positive surprise thrice in the four trailing quarters with an average beat of 59.31%.
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Novartis (NVS) Reports Favorable Data on Enbrel Biosimilar
Novartis AG’s (NVS - Free Report) generic arm, Sandoz announced the publication of results from EGALITY study in the British Journal of Dermatology. The study showed that its biosimilar version of Amgen Inc.’s (AMGN - Free Report) blockbuster drug, Enbrel, Erelzi, is equivalent to the originator product in more than 500 adult patients over 52 weeks.
Erelzi was approved by the FDA in August this year for the treatment of various inflammatory conditions including rheumatoid arthritis, plaque psoriasis and psoriatic arthritis. The biosimilar candidate is under review in the EU where the submission was accepted last year. Notably, Erelzi is still to be launched in the U.S.
EGALITY included both the switched and continuous treatment arms. Patients were treated with Erelzi and Enbrel alternatively and it was seen that no clinically meaningful difference in safety and efficacy were observed between Erelzi and the originator product over the duration of the study. In addition the three treatment switches had no impact on the safety and efficacy of the biosimilar candidate.
Sandoz currently markets Zarxio in the U.S. a biosimilar version of Amgen Inc.’s (AMGN - Free Report) Neupogen. In addition, it has a strong pipeline of biosimilars including that of Roche Holding AG’s (RHHBY - Free Report) Rituxan. The company plans to launch five biosimilars for major oncology and immunology biologics across key geographies by 2020. Sandoz is well positioned in the biosimilars space based on its experience and capabilities in development, manufacturing and commercialization.
Novartis currently carries a Zacks Rank #3 (Hold).
A Stock to Consider
A better-ranked stock in the healthcare sector is Arbutus Biopharma Corporation (ABUS - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Arbutus’s loss estimates narrowed from $2.15 to $1.74 for 2016 and from $1.96 to $1.51 for 2017 over the last 60 days. The company posted a positive surprise thrice in the four trailing quarters with an average beat of 59.31%.
NOVARTIS AG-ADR Price
NOVARTIS AG-ADR Price | NOVARTIS AG-ADR Quote
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>